Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats

Journal of Pharmaceutical Sciences

Volumn 97, Issue 10, 2008, Pages 4546-4556

  Wang, Xiaodong ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

7,8 Benzoflavone; ADME; BCRP; Bioavailability; Drug interaction; Oral absorption; Pharmacokinetics

Indexed keywords

ALPHA NAPHTHOFLAVONE; BREAST CANCER RESISTANCE PROTEIN; NITROFURANTOIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

EID: 55749111891     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21296     Document Type: Article

References (26)

1. Stermitz FR, Bais HP, Foderaro TA, Vivanco JM. 2003. 7,8-Benzoflavone: A phytotoxin from root exudates of invasive Russian knapweed. Phytochemistry 64:493-497.
2. Lee HS, Jin C, Park J, Kim DH. 1994. Modulation of cytochrome P450 activities by 7,8-benzoflavone and its metabolites. Biochem Mol Biol Int 34:483-491.
3. Koley AP, Buters JT, Robinson RC, Markowitz A, Friedman FK. 1997. Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone. J Biol Chem 272:3149-3152.
4. Boek-Dohalska L, Hodek P, Sulc M, Stiborova M. 2001. alpha-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3 A6. Chem Biol Interact 138:85-106.
5. Kellis JT Jr, Vickery LE. 1984. Inhibition of human estrogen synthetase (aromatase) by flavones. Science 225:1032-1034.
6. Meinhardt U, Mullis PE. 2002. The essential role of the aromatase/p450arom. Semin Reprod Med 20:277-284.
7. Dhawan K, Kumar S, Sharma A. 2002. Beneficial effects of chrysin and benzoflavone on virility in 2-year-old male rats. J Med Food 5:43-48.
8. Zhang S, Yang X, Morris ME. 2004. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216.
9. Mao Q, Unadkat JD. 2005. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133.
10. Zhang S, Yang X, Coburn RA, Morris ME. 2005. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70:627-639.
11. Wang X, Morris ME. 2007. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: Potential involvement of AB CG2. Drug Metab Dispos 35:268-274.
12. Galijatovic A, Otake Y, Walle UK, Walle T. 1999. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 29:1241-1256.
13. Moon YJ, Sagawa K, Frederick K, Zhang S, Morris ME. 2006. Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J 8:E433-E442.
14. Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV. 2001. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 51:143-146.
15. Ji Y, Kuo Y, Morris ME. 2005. Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res 22:1658-1666.
16. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. 2005. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764.
17. van Herwaarden AE, Schinkel AH. 2006. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27:10-16.
18. Lee CA, Manyike PT, Thummel KE, Nelson SD, Slattery JT. 1997. Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes. Drug Metab Dispos 25:1150-1156.
19. Lee HS, Jin CB, Chong HS, Yun CH, Park JS, Kim DH. 1994. Involvement of P4503A in the metabolism of 7,8-benzoflavone by human liver microsomes. Xenobiotica 24:1053-1062.
20. Nesnow S, Bergman H. 1981. Metabolism of alpha-naphthoflavone by rat liver microsomes. Cancer Res 41:2621-2626.
21. Imai Y, Tsukahara S, Asada S, Sugimoto Y. 2004. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346-4352.
22. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD. 2005. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326:181-187.
23. Takizawa Y, Morota T, Takeda S, Aburada M. 2003. Pharmacokinetics of (-)-epicatechin-3-O-gallate, an active component of Onpi-to, in rats. Biol Pharm Bull 26:608-612.
24. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
25. Ferry DR, Smith A, Malkhandi J, Fyfe DW, de Takats PG, Anderson D, Baker J, Kerr DJ. 1996. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659-668.
26. Li Y, Pan WS, Chen SL, Xu HX, Yang DJ, Chan AS. 2006. Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Dev Ind Pharm 32:413-422.